Adjusted HRs for mortality associated with PDE5i use by subgroups with prior history of co-morbid conditions in the naïve and imputed cohorts
| Naïve cohort unadjusted | Naïve cohort adjusted* | Imputed cohort* | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | |
| All men | 0.69 (0.60 to 0.79) | <0.0001 | 0.83 (0.72 to 0.95) | 0.009 | 0.73 (0.63 to 0.84) | <0.001 |
| Prior AMI | 0.59 (0.43 to 0.80) | 0.001 | 0.73 (0.53 to 0.99) | 0.045 | 0.63 (0.46 to 0.85) | 0.003 |
| Prior CCF | 0.64 (0.47 to 0.87) | 0.005 | 0.76 (0.55 to 1.04) | 0.086 | 0.64 (0.46 to 0.87) | 0.005 |
| Prior AF | 0.77 (0.58 to 1.02) | 0.077 | 0.92 (0.68 to 1.25) | 0.598 | 0.74 (0.55 to 0.99) | 0.044 |
| Prior stroke | 0.65 (0.42 to 1.03) | 0.068 | 0.82 (0.51 to 1.31) | 0.045 | 0.62 (0.39 to 0.99) | 0.045 |
| Prior TIA | 0.60 (0.38 to 0.95) | 0.031 | 0.77 (0.47 to 1.24) | 0.276 | 0.57 (0.36 to 0.92) | 0.021 |
| Prior PVD | 0.66 (0.48 to 0.93) | 0.016 | 0.76 (0.54 to 1.07) | 0.123 | 0.69 (0.49 to 0.96) | 0.030 |
Naïve cohort refers to the unimputed cohort.
*Adjusted for age, smoking status and statin use for each subgroup.
AF, atrial fibrillation; AMI, acute myocardial infarction; CCF, congestive cardiac failure; PDE5i, phosphodiesterase type-5 inhibitor; PVD, peripheral vascular disease; TIA, transient ischaemic attack.